Translational Lung Cancer Research

Article	Citations
Prolonged disease control with local treatments in oligo-acquired resistance to immune-checkpoint inhibitors	52
Density and maturity ratio of tertiary lymphoid structures in stage II–III non-small cell lung cancer predict postoperative recurrence risk	50
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer	42
Evaluation of gut leakage and bacterial translocation as efficacy biomarkers of immunotherapy in advanced non-small cell lung cancer (NSCLC)	40
Whole genome characterization of patient-derived lung cancer organoids	38
Comparison of efficacy and surgery-related safety of perioperative tislelizumab and pembrolizumab with neoadjuvant chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study	35
Tackling the challenge of brain involvement in driver-negative non-small cell lung cancer	33
DNA hypomethylation-activated PRAME drives early-stage lung adenocarcinoma recurrence via ZNF740 and PI3K/AKT/mTOR signaling	30
Contrast-enhanced CT and PET-CT characteristics of primary tracheal lymphoepithelioma-like carcinoma: case series	29
Long-term survival after combination therapy with atezolizumab in a patient with small-cell lung cancer: a case report	28
Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer	28
Targeting ferroptosis to overcome drug resistance in lung cancer	27
PFKP confers chemoresistance by upregulating ABCC2 transporter in non-small cell lung cancer	27
The epidemic of malignant mesothelioma in China: a prediction of incidence during 2016–2030	27
Prognostic factors of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor (TKI): a nationwide registry study in China	26
Metachronous development of L858R and T790M EGFR mutations following ALK inhibitor therapy in stage IV lung adenocarcinoma: a case report	26
Molecular and clinical disparity of EGFR-mutant non-small cell lung cancer (NSCLC) based on histopathological stage and EGFR molecular subtypes	26
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review	26
Real-world data on severe lung cancer: a multicenter retrospective study	25
Microbiota modulate lung squamous cell carcinoma lymph node metastasis through microbiota-geneset correlation network	25
Efficacy and safety of lorlatinib in first-line and subsequent-line treatments for patients with ALK-positive non-small cell lung cancer: a single-center real-world study in China	25
Optimizing long-term treatment with ALK inhibitors: balancing efficacy and safety	24
Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression	24
Predictive value of perioperative carcinoembryonic antigen changes for recurrence in non-small cell lung cancer	24
Discrepancies in PD-L1 expression, lymphocyte infiltration, and tumor mutational burden in non-small cell lung cancer and matched brain metastases	23

Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study	23
Needle tract seeding after endobronchial ultrasound-guided intranodal forceps biopsy and cryobiopsy: a case report	23
Change of bone mineral density as a prognostic marker in small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study	23
Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations?	22
Dynamic change of CD8+ T cell: immunotherapy fate tell?	22
Identification of distinct tumor cell patterns with single-cell RNA sequencing integrating primary lung adenocarcinoma and brain metastasis tumor	20
KEYNOTE-407: an effective and safe first-line treatment option for metastatic squamous non-small cell lung cancer	20
Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?	20
Efficacy and safety of camrelizumab plus apatinib in previously treated patients with advanced non-small cell lung cancer harboring EGFR or ALK genetic aberration	20
Sacituzumab govitecan: a new hope for patients with pretreated extensive small-cell lung cancer (SCLC)—insights from the TROPiCS-03 trial	20
Survival outcomes and risk factors after lung transplantation in patients with pre-transplant malignancy: a national cohort study	20
Tackling a caveat of the FLAURA trial and building solid evidence for frail patients in thoracic oncology	19
DNA methylation profiling in early lung adenocarcinoma to predict response to immunotherapy	19
Prognostic factors affecting mortality in elderly, low body mass index, and poor performance status groups with lung cancer: analysis of the 2016 Korean Association of Lung Cancer Registry (KALC-R) da	19
Treatment patterns and clinical outcomes of resectable central non-small cell lung cancer patients undergoing sleeve lobectomy: a large-scale, single-center, real-world study	19
Prospective evaluation of immunological, molecular-genetic, image-based and microbial analyses to characterize tumor response and control in patients with unresectable stage III NSCLC treated with con	19
PD-L1 expression as a prognostic factor for postoperative outcomes in pleural mesothelioma	18
Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial	18
Impact of baseline brain metastases on survival and CNS progression in NSCLC patients treated with immune checkpoint inhibitors in real-world studies: a systematic review and meta-analysis	18
Hyperthermic intrathoracic chemotherapy in overcoming tyrosine kinase inhibitor resistance in a patient with malignant pleural effusion: a case report	18
The opportunities and challenges of perioperative therapy of localized non-small cell lung cancer—thoughts from the KEYNOTE-671 trial	18
Integrative modeling of longitudinal cell-free DNA and tumor volume dynamics: a multimodal quantitative prognostic framework	18
Development of an AI model for predicting hypoxia status and prognosis in non-small cell lung cancer using multi-modal data	18
Comparative survival outcomes between EGFR-wildtype and EGFR-mutant lung adenocarcinoma following neoadjuvant chemoimmunotherapy: a retrospective cohort study from national cancer center in China	18
Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?	18
Connecting the dots: (RANKL+) extracellular vesicle count in blood plasma in relation to bone metastases, skeletal related events and osimertinib treatment in patients with EGFR mutated non-small cell	18
Neoadjuvant immunochemotherapy in potentially resectable small cell lung cancer: a real-world retrospective analysis	18
Some like it hot: the potential role of hyperthermic intrathoracic chemotherapy in the multimodality treatment of pleural mesothelioma	18
Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a Mendelian randomization study	17
Diagnostic accuracy and safety of electromagnetic navigation transthoracic needle biopsy under moderate sedation for the diagnosis of peripheral pulmonary lesions	17
Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study	17
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer	17
Potential efficacy of anti-angiogenic therapy combined with immunotherapy for advanced SMARCA4-deficient thoracic tumor: a retrospective study	17
Tarlatamab: the promising immunotherapy on its way from the lab to the clinic	16
Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer	16
A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA	16
Advancements of ALK inhibition of non-small cell lung cancer: a literature review	16
The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer	16
Another point of view for meta-analysis studies focused on protective inhaled corticosteroids and the risk of lung cancer	15
Follow-up regimen after lung cancer treatment: about the how and why	15
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1-rearranged N	15
Navigating treatment sequencing in ALK-positive non-small cell lung cancer: lorlatinib as a key to prolonged survival?	15
Efficacy of targeted therapy in patients with non-small cell lung cancer harboring very rare mutations in EGFR exon 18	15
Expression of YAP1 delineates distinct subtypes of pulmonary large cell neuroendocrine carcinoma with divergent therapeutic implications	15
Homologous recombination pathway gene variants identified by tumor-only sequencing assays in lung carcinoma patients	15
Exploration of a novel prognostic model based on nomogram in non-small cell lung cancer patients with distant organ metastasis: implications for immunotherapy	14
Are polygenic risk scores ready for the cancer clinic?—a perspective	14
Development and validation of a dynamic survival nomogram for metastatic non-small cell lung cancer based on the SEER database and an external validation cohort	14
Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I–IIIA NSCLC	14
Health-related quality of life analysis from ENTER, a randomized, controlled phase III trial of whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases	14

Spontaneous ventilation video-assisted thoracoscopic surgery for octogenarian non-small cell lung cancer patients: a non-inferiority study	14
Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor—a Danish cohort study	14
Will “Sun”-WUKONG, the monkey king, conquer EGFR exon 20 insertion mutation positive non-small cell lung cancer?	13
Advances in the research on radiotherapy for lung cancer: a 2025 review	13
Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study	13
LungPath: artificial intelligence-driven histologic pattern recognition for improved diagnosis of early-stage invasive lung adenocarcinoma	13
Enhancing the sensitivity of lung adenocarcinoma to immune therapeutic agents through SPRED1	13
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer	13
Clinical features and prognostic biomarkers in patients with SMARCA4-mutated non-small cell lung cancer	13
DLL3-targeted CAR T-cell therapy in pre-clinical models for small cell lung cancer: safety, efficacy, and challenges	13
Treatment interruption during neoadjuvant immuno-chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials	13
Patient-reported impact of symptoms in lung cancer (PRISM-LC)	13
Lightweight hybrid foundation model for lung cancer prognosis based on low-dose chest X-ray images	13
International cost-effectiveness analysis of durvalumab consolidation treatment after chemoradiotherapy for patients with limited-stage small-cell lung cancer	13
Evaluating three-dimensional lung reconstructions for thoracoscopic lung resections using open-source software: a pilot study	13
Stage- and smoking-associated microRNA expression in lung adenocarcinoma	13
The long-term oncologic outcomes of robot-assisted bronchial single sleeve lobectomy for 104 consecutive patients with centrally located non-small cell lung cancer	12
Response to platinum-based therapies in second-line after immunotherapy in advanced or metastatic non-small-cell lung cancer PD-L1 ≥50%	12
Clinicopathological characteristics and prognostic significance of HDAC11 protein expression in non-small cell lung cancer: a retrospective study	12
Mid-term efficacy and safety of transbronchial cryoablation for stage IA peripheral lung cancer: a retrospective analysis	12
Single-cell and spatial transcriptomics reveal a potential role of ATF3 in brain metastasis of lung adenocarcinoma	12
Pulmonary ground glass opacity tumor: a curable subtype of lung cancer when treated within the “surgical curative time window”	12
Maintenance therapy for metastatic non-squamous non-small cell lung cancer: efficacy and biomarker analysis of pemetrexed discontinuation	12
Preclinical evaluation of thin convex probe endobronchial ultrasound-guided transbronchial needle aspiration for intrapulmonary lesions	12
Lower respiratory tract microbiome is associated with checkpoint inhibitor pneumonitis in lung cancer patients	12
Association between patient-reported outcomes and pathological response in neoadjuvant chemoimmunotherapy—a post hoc analysis of the TD-FOREKNOW trial	12
Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions	12
Research into overcoming drug resistance in lung cancer treatment using CRISPR-Cas9 technology: a narrative review	12
Completion lobectomy following segmentectomy for malignant lung tumors: a multi-institutional study of surgical feasibility, oncologic outcomes, and diagnostic challenges (ESSG-02 study)	12
Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: a narrative review	12
A case series of nonintubated robotic-assisted bronchoscopy: a feasible alternative to intubated techniques	12
One-year mortality risk prediction model for patients with interstitial lung disease and lung cancer	12
Cancer cachexia research: coming of age	12
Lung cancer susceptibility beyond smoking history: opportunities and challenges	11
Clinical characteristics, surgical treatments, prognosis, and prognostic factors of primary tracheal cancer patients: 20-year data of the National Cancer Center, China	11
Enhancing the precision of auxiliary diagnosis for lung cancer through use of SHOX2 and RASSF1A methylation status in lung biopsy and lymph node biopsy specimens	11
Paving the way for ctDNA-guided trials in lung cancer: insights from the LIBELULE study	11
A prospective phase 2 study of expeditious EGFR genotyping and immediate therapeutic initiation through extracellular vesicles (EV)-based bronchoalveolar lavage fluid (BALF) liquid biopsy in advanced	11
Mechanistic insights into the immune biomarker of perioperative immune checkpoint inhibitors for non-small cell lung cancer	11
Radiotherapy as salvage therapy and an adjunct to immunotherapy: exploring local and abscopal mechanisms to overcome immunotherapy resistance: a narrative review	11
Future lung cancer prediction using low-dose chest computed tomography	11
Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer	11
Association of cholesterol and triglyceride levels with the recurrence of early-stage lung adenocarcinoma with micropapillary pattern	11
Predictive value of the monocyte-to-high-density lipoprotein ratio in the prognosis of non-small cell lung cancer patients after surgery	11
Exploring the efficacy of artificial neural networks in predicting lung cancer recurrence: a retrospective study based on patient records	11
PD-1 expression on tumor cells: a new target for cancer therapy	11
Dual immuno-oncology agents as neoadjuvant therapy for patients with resectable non-small cell lung cancer	11
Outcomes and prognostic insights in primary tracheal cancer: a multicenter retrospective study	11
Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally ad	10
Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple ALK fusions treated with tyrosine kinase inhibitors	10
Immune-related osteoblastic bone alterations mimicking bone metastasis in a small-cell lung cancer patient treated with durvalumab: a case report	10
Exosomal miR-182-5p is a potential diagnostic marker for malignant pleural effusion	10
Targeted therapy for stage IA non-small cell lung cancer with EGFR mutations: a scoping review	10
Subtype-specific RNA sequencing using micro-dissection revealed extracellular matrix alterations as key factors in lung adenocarcinoma invasion	10
Clinical and prognostic significance of detecting CEA, EGFR, LunX, c-met and EpCAM mRNA-positive cells in the peripheral blood, tumor-draining blood and bone marrow of non-small cell lung cancer patie	10
Integrating deep learning and radiomics in the differentiation of major histological subtypes of invasive non-mucinous lung adenocarcinoma using positron emission tomography and computed tomography	10
First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic	10
Development and validation of an interpretable machine learning model for prediction of occult lymph node metastasis in clinical stage T1 lung adenocarcinoma	10
Real-time breath metabolomics as catalyst for personalized lung cancer diagnostics: prospective matched case-control trial (LUCAbreath)	10
A comprehensive clinical trajectory of EGFR A763_Y764insFQEA-positive non-small cell lung cancer treated with fifth-line osimertinib following circulating tumor DNA-based detection: a case report	10
Assessing current diagnostic, staging, and treatment practices in community and academic centers for individuals with stage IB–IIIA non-small cell lung cancer	10
Tumor immune microenvironment analysis of non-small cell lung cancer development through multiplex immunofluorescence	9
A retrospective study for prognostic significance of type II diabetes mellitus and hemoglobin A1c levels in non-small cell lung cancer patients treated with pembrolizumab	9
Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancer	9
SMARCA4 deficiency: implications for non-small cell lung cancer and management strategies, with relevance to and distinctions from thoracic undifferentiated tumor	9
Natural course of lung adenocarcinoma manifesting as ground-glass nodules: invasiveness assessment based on growth evaluation	9
From tradition to transformation: evolving paradigms in surgical lung cancer treatment	9
Identification of lysosomal genes associated with prognosis in lung adenocarcinoma	9
Predictive value of longitudinal systemic inflammatory markers for pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer	9
The prognostic role of albumin levels in lung cancer patients receiving third-line or advanced immunotherapy: a retrospective study	9
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer	9
Determinants of Aurora kinase B inhibitor sensitivity in small cell lung cancer	9
Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow	9
Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers	9
Integrating radiomics and deep learning for enhanced prediction of high-grade patterns in stage IA lung adenocarcinoma	9
False positivity in break apart fluorescence in-situ hybridization due to polyploidy	9
Cellular senescence and lung cancer prognosis	9
CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study	9
Lymph node dissection of station 8 improves the survival of T≤3 cmN0M0 lung adenocarcinoma patients	9
Radiomic phenotypes of oligometastatic non-small cell lung cancer	9

Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review	8
Penetrating the central nervous system sanctuary of KRAS, a target once thought “undruggable”	8
Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring HER2 exon 19, p.L755P mutation: case report	8
Utility of ctDNA-molecular residual disease in predicting minimal residual disease in non-small cell lung cancer patients after radical resection	8
Metabolite biomarkers in lung cancer: unlocking the potential of body fluid analysis for early detection and prognosis—a narrative review	8
Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis	8
Knowledge and beliefs about lung cancer screening among Black individuals at high risk: a qualitative approach	8
Age at first sexual intercourse, age at menarche, and age at menopause: a mendelian randomization study on lung cancer risk	8
NOTCH4 as a driver of epithelial-mesenchymal transition, angiogenesis, and stromal remodeling in lung adenocarcinoma: integrated transcriptomic and protein-level validation	8
Is seeing believing?—signal differentiation in a preclinical transbronchial imaging study implementing a composite optical fiber bronchoscope to detect a folate receptor-targeted near-infrared fluorop	8
Fluorofenidone enhances cisplatin efficacy in non-small cell lung cancer: a novel approach to inhibiting cancer progression	8
Association of PD-L1 expression with systemic immune parameters in non-small cell lung cancer	8
Comparative efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy versus combined EGFR-TKI and chemotherapy in resectable EGFR-mutant non-small cell lung cancer	8
The OPEN trial—from the darkness, comes light	8
Learning curve for uniportal thoracoscopic pulmonary segmentectomy: how many procedures are required to acquire expertise?	8
What do we know about the role of neoadjuvant targeted therapy in early-stage EGFR-mutant and ALK-fused non-small cell lung cancer?—a narrative review of the current literature	8
Construction and validation of deep learning model for cachexia in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors: a multicenter study	8
Higher proximity of PD-L1+ tumor cells to PD-1+ tissue-resident memory CD8 determines response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer	8
Good responses to first-line immunotherapy-included treatment in lung squamous carcinoma with rare driver gene mutations: a report of three cases	8
Comprehensive analysis of next generation sequencing and ARMS-PCR for detecting EGFR exon 20 insertion (ex20ins) mutations in Chinese non-small cell lung cancer patients	8
Epidermal growth factor receptor exon 20 insertion mutations: are we getting closer to solving the puzzle?	8
Reducing radiation pneumonitis in lung cancer patients: from Chinese expert consensus to practice	8
Racial disparities in histological subtype, stage, tumor grade and cancer-specific survival in lung cancer	8
Efficacy and safety of consolidative thoracic radiotherapy after first-line chemoimmunotherapy in patients with extensive-stage small-cell lung cancer: a retrospective cohort study	8
Oncogene-addicted solid tumors and microbiome—lung cancer as a main character: a narrative review	8
Fibre-based fluorescence-lifetime imaging microscopy: a real-time biopsy guidance tool for suspected lung cancer	8
Altered carnitine transporter genes (SLC22A5, SLC22A16, SLC6A14) expression pattern among lung cancer patients	8
Radiotherapy vs. photodynamic therapy: a comparison of antitumor effects and pulmonary toxicity in preclinical models	7
Systemic immune index predicts tumor-infiltrating lymphocyte intensity and immunotherapy response in small cell lung cancer	7
Investigation of non-completion factors for durvalumab maintenance therapy in locally advanced non-small cell lung cancer	7
Rechallenge of afatinib for EGFR-mutated non-small cell lung cancer previously treated with osimertinib: a multicenter phase II trial protocol (REAL study)	7
Invasive mucinous adenocarcinoma harbored MET exon 14 skipping mutation: case report	7
Biomarkers as a tool to reduce disparities in lung cancer screening and detection	7
A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma	7
BRAF RNA is prognostic and widely expressed in lung adenocarcinoma	7
Prognostic value of L4 lymph node dissection during video-assisted thoracoscopic surgery in patients with left-sided non-small cell lung cancer: a single-center, retrospective cohort study	7
DeepGR: a deep-learning prognostic model based on glycolytic radiomics for non-small cell lung cancer	7
Triple-targeted therapy of dabrafenib, trametinib, and osimertinib for the treatment of the acquired BRAF V600E mutation after progression on EGFR-tyrosine kinase inhibitors in advanced EGFR-mutated n	7
Extending the clinical indications of liquid biopsy: plasma next-generation sequencing in suspected lung cancer	7
Differential impact of intratumor heterogeneity (ITH) on survival outcomes in early-stage lung squamous and adenocarcinoma based on tumor mutational burden (TMB)	7
Multidisciplinary international expert consensus on perioperative airway management	7
Metabolic phenotype and gender may predict treatment outcomes of atezolizumab in extensive-stage small cell lung cancer	7
Efficacy of neoadjuvant immunochemotherapy in the treatment of stage III non-small-cell lung cancer with cancer driver gene mutations	7
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review	7
Re-administration of immune checkpoint inhibitors for patients with non-small cell lung cancer	7
Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study	7
Prognostic implications of MDM2 expression in surgically resected epidermal growth factor receptor mutant lung cancer with pathological lymph node metastasis	7
Current advances in mediastinal staging for non-small cell lung cancer: a narrative review	7
Cerebrospinal fluid cytology for the diagnosis of lung cancer brain metastasis: a case report	7
Local consolidative therapy for the primary tumor in EGFR-mutant advanced non-small cell lung cancer following osimertinib plus chemotherapy: a protocol for a single-arm, open-label, phase 2 trial	7
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22	7
Impact of lymph node dissection on cancer-specific survival in non-small cell lung cancer patients: a SEER database analysis	7
Targeting a cure in anaplastic lymphoma kinase-positive non-small cell lung cancer	7
The IASLC grading system as a predictor for EGFR-TKI therapy in patients with EGFR-mutant lung adenocarcinoma	7
Increased serum levels of KiSS1-derived peptides in non-small cell lung cancer patient liquid biopsies and biological relevance	7
Integrative genomic profiling reveals characteristics of lymph node metastasis in small cell lung cancer	7
Pneumonectomy—a necessary evil?	7
The APPLE trial in the evolving landscape of ctDNA monitoring	7
Safety and efficacy of transbronchial radiofrequency ablation for stage IA peripheral lung cancer: a retrospective cohort study	7
STING facilitates the development of radiation-induced lung injury via regulating the PERK/eIF2α pathway	7
Deep learning model for predicting spread through air spaces of lung adenocarcinoma based on transfer learning mechanism	7
Comprehensive management of MET tyrosine kinase inhibitor-induced peripheral edema in patients with MET-altered non-small-cell lung cancer: a narrative review	7
The association between clinical parameters and resectability in stage III non-small cell lung cancer, and a combination of N2 lymph node burden and lung immune prognostic index score as a potential b	7
Neoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review	7
Residual tumor descriptors proposed by the International Association for the Study of Lung Cancer may not be applicable to stage I and ground-glass opacity-featured non-small cell lung cancer	7
A new hope for aggressive thoracic cancers: foundational efficacy of frontline immunotherapy in SMARCA4-deficient tumors	6
PD-L1 expression in non-small cell lung carcinoma in Latin America: a systematic review and meta-analysis	6
Association of systemic therapy with survival among adults with advanced non-small cell lung cancer	6
MiR-200a regulates PD-L1 and predicts response to immune checkpoint inhibitors in advanced non-small cell lung cancer	6
Electromagnetic navigation bronchoscopy for localization of bilateral multiple pulmonary nodules: a comparative evaluation of safety and efficacy	6
Ion robotic bronchoscopy laser ablation and Da Vinci robotic segmentectomy for bilateral pulmonary nodules: a case report	6
Comparative study of bronchoscopic and CT-guided percutaneous microwave ablation for inoperable non-small cell lung cancer	6
Clinical application of three-dimensional reconstruction in anatomical analysis of the right anterior, lateral, and posterior basal segments (RS8, RS9, and RS10) for RS9 segmentectomy	6
NLRP3 activation in tumor-associated macrophages enhances lung metastasis of pancreatic ductal adenocarcinoma	6
A potential central nervous system niche for trastuzumab deruxtecan in patients with HER2-expressing non-small cell lung cancer	6
PD-L1 expression in primary lung tumor as a superior predictive biomarker to metastatic lymph nodes for first-line immunochemotherapy in advanced KRAS-mutant non-small cell lung cancer	6
Recurrence prediction of lung adenocarcinoma using an immune gene expression and clinical data trained and validated support vector machine classifier	6
Primary resistance to ALK inhibitors in KLC1/ALK-rearranged pleural metastatic lung adenocarcinoma: a case report	6
Genomic alterations dissection revealed MUC4 mutation as a potential driver in lung adenocarcinoma local recurrence	6
Value of 18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in the differential diagnosis of sarcoidosis and lung cancer with lymph node metastasis: a retrospectiv	6
Evaluation of the novel International Association for the Study of Lung Cancer grading system in adenocarcinoma with spread through air space	6
EGFR exon 20 insertion mutation and MET exon 14 skipping mutation in non-small cell lung cancer: a scoping review in the Chinese population	6
Fructose-diphosphate aldolase C as a novel diagnostic biomarker for early-stage non-small cell lung cancer: a low-abundance proteomics study	6
Two-year treatment-free sustained remission after chemo-immunotherapy in a 52-year-old male with recurrent ARID1A-mutant lung adenocarcinoma: a case report	6
Prognostic impact of negative TTF-1 biomarker in metastatic lung adenocarcinoma treated with chemo-immunotherapy: a retrospective cohort study	6
Adjuvant therapies in stages I–III epidermal growth factor receptor-mutated lung cancer: current and future perspectives	6
Endoplasmic reticulum stress-related genes contribute to lung cancer risk: a multiomics data integration study	6
Construction and validation of a novel ferroptosis-related prognostic signature for lung adenocarcinoma	6
KMT2C expression and DNA homologous recombination repair factors in lung cancers with a high-grade fetal adenocarcinoma component	6
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study	6
TQB2450 with or without anlotinib as maintenance treatment in subjects with locally advanced/unresectable non-small cell lung cancer that have not progressed after prior concurrent/sequential chemorad	6
Shift in lung cancer stage at diagnosis during the COVID-19 pandemic in New York City	6
A CT imaging-based deep learning model for predicting EGFR and KRAS mutations in non-small cell lung cancer: toward personalized treatment approaches	6
Association between changes in thioredoxin reductase and other peripheral blood biomarkers with response to PD-1 inhibitor-based combination immunotherapy in non-small cell lung cancer: a retrospectiv	6
Incremental prognostic value of solid component volume ratio and entropy for pathological stage IA invasive lung adenocarcinoma after surgery	6